Literature DB >> 8055487

Cisplatin: a clinical review. Part I--Current uses of cisplatin and administration guidelines.

M E Cooley1, L E Davis, M DeStefano, J Abrahm.   

Abstract

Cisplatin is one of the most active cancer treatment agents available. Unfortunately, however, cisplatin causes many untoward side effects. Nurses play a major role in administering cisplatin and in preventing and managing the adverse effects associated with this drug. In order to maximize the quality of life of patients undergoing cisplatin treatment, nurses need a thorough knowledge of its uses, administration, and side effects. This article is the first of a two-part series about cisplatin. Part I will provide a review of the mechanism of action, current uses, and administration guidelines. Part II will discuss the most common side effects of cisplatin and the appropriate nursing assessment and management of patients undergoing treatment with this agent. In addition, future directions for the use of cisplatin and the use of alternative agents will be discussed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8055487

Source DB:  PubMed          Journal:  Cancer Nurs        ISSN: 0162-220X            Impact factor:   2.592


  7 in total

1.  Cisplatin nephrotoxicity is not detected by urinary cell-cycle arrest biomarkers in lung cancer patients.

Authors:  Zeki Toprak; Egemen Cebeci; Serife Aysen Helvaci; Ilkim Deniz Toprak; Yasin Kutlu; Abdullah Sakin; Tufan Tukek
Journal:  Int Urol Nephrol       Date:  2017-03-02       Impact factor: 2.370

2.  Selenium Status in Diet Affects Nephrotoxicity Induced by Cisplatin in Mice.

Authors:  Shuang Liu; Xing Wen; Qihan Huang; Minghui Zhu; Jun Lu
Journal:  Antioxidants (Basel)       Date:  2022-06-10

3.  Antitumor Activity of 2,9-Di-Sec-Butyl-1,10-Phenanthroline.

Authors:  Dongsheng Wang; Shifang Peng; A R M Ruhul Amin; Mohammad Aminur Rahman; Sreenivas Nannapaneni; Yuan Liu; Dong M Shin; Nabil F Saba; Jack F Eichler; Zhuo G Chen
Journal:  PLoS One       Date:  2016-12-29       Impact factor: 3.240

4.  The synergistic cytotoxic effect of cisplatin and honey bee venom on human ovarian cancer cell line A2780cp.

Authors:  Masoumehzaman Alizadehnohi; Mohammad Nabiuni; Zahra Nazari; Zahra Safaeinejad; Saeed Irian
Journal:  J Venom Res       Date:  2012-10-23

5.  Potentiation of a novel palladium (II) complex lethality with bee venom on the human T-cell acute lymphoblastic leukemia cell line (MOLT-4).

Authors:  Zahra Safaeinejad; Mohammad Nabiuni; Zahra Nazari
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2013-10-03

6.  Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells.

Authors:  Sanjeevani Arora; Joshua Heyza; Hao Zhang; Vivian Kalman-Maltese; Kristin Tillison; Ashley M Floyd; Elaine M Chalfin; Gerold Bepler; Steve M Patrick
Journal:  Oncotarget       Date:  2016-11-15

7.  Gap Junction Intercellular Communication Positively Regulates Cisplatin Toxicity by Inducing DNA Damage through Bystander Signaling.

Authors:  Sanjeevani Arora; Joshua R Heyza; Elaine C Chalfin; Randall J Ruch; Steve M Patrick
Journal:  Cancers (Basel)       Date:  2018-10-02       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.